Open AccessBaseline Genotypic and Phenotypic Susceptibilities of HIV-1 Group O to Enfuvirtide
Author(s) -
Agnès Depatureaux,
Charlotte Charpentier,
Gilles Collin,
Marie Leoz,
Diane Descamps,
Aurélia Vessière,
Florence Damond,
Dominique Rousset,
Françoise BrunVézinet,
JeanChristophe Plantier
Publication year - 2010
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00100-10
Subject(s) - enfuvirtide , genotype , biology , virology , phenotype , human immunodeficiency virus (hiv) , drug resistance , gp41 , genetics , gene , antigen , epitope
We assessed the natural genotypic and phenotypic susceptibilities to enfuvirtide of 171 HIV group O (HIV-O) samples and 29 strains, respectively. The N42D resistance-associated mutation in the gp41 region was detected in 98% of cases. The phenotypic assay showed a wide range of baseline susceptibilities, with 50% inhibitory concentrations (IC50 s) from 4 to 5,000 nM, a range similar to that reported for HIV-1 group M. Thus, despite the natural genotypic resistance conferred by the N42D signature mutation, HIV-O variants appear to be phenotypically susceptible. Enfuvirtide could therefore potentially be used in antiretroviral treatments for HIV-O-infected patients.